The hot new buzzword in tech is synthetic biology. Its main purveyor is a startup with hundreds of millions in investment and a valuation of [dollar]4.2 billion. Gingko Bioworks CEO Jason Kelly spoke with Bloomberg Businessweek Editor Joel Weber about how his company plans to change the world, from genes on up
Notes
Title from resource description page (viewed April 18, 2022)
